Navigation Links
Cord Blood America Says Outreach Program to OB/GYN Nurses, Insurance Case Workers, Paying Significant Dividends
Date:9/8/2010

LAS VEGAS, Sept. 8 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today Dr. Geoffrey John O'Neill, its Medical Director, was interviewed by analyst Francis Gaskins. The interview concerned the Company's outreach program to nurses and case workers on the value of storing umbilical cord blood.

The entire interview is available at: http://gaskinsco.com/cbai-9-2-10.mp3

In the interview, Dr. O'Neill explains the importance of talking to case workers for insurance companies, and OB/GYN nurses about the value of cord blood storage.  "These are the people who are in constant contact with the pregnant patient and her family.  Doctors are often too busy to spend the time on this issue.  No other company has an outreach program like we do and we are very proud of it and its successes."

Prior to joining Cord Blood America, Dr. O'Neill was Laboratory and Scientific/Medical Director for Cryo-Cell International Inc. in Florida and was Laboratory Director for the Bio-Matrix Scientific Group Inc., a San Diego biotech research and development firm in the stem cell sector.  He received a Ph.D. in Immunology from the University of Glasgow, Scotland, and is the author or co-author of more than 75 publications in his field in which he has won a number of significant honors.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT:

Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com




'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments
2. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
3. Cord Blood America Reports 12% Increase in 2010 Second Quarter Revenue
4. China Cord Blood Corporation Announces Cancellation of Nine Million Management Incentive Warrants
5. China Cord Blood Corporation Joins Russell Global Index
6. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
7. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
8. Scientists Give the Go-Ahead for Private Storage of Stem Cells From Umbilical Cord Blood
9. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
10. FirstAidWarehouse.co.uk Examines High Blood Pressure, or Hypertension, and Blood Pressure Monitors
11. New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):